Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of BTP0611 extended-release tablets versus ivabradine hydrochloride tablets in chronic heart failure with reduced ejection fraction
CTR20250267Phase 3Active
- Sponsor
- Novabio
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BTP0611 in chronic heart failure (CHF), heart failure with reduced ejection fraction (HFrEF), sponsored by Novabio. Started Apr 2025; status: active.
02
Drugs
BTP0611
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20250267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250267.